Enzypep B.V.
Records under this name other than patents Enzypep B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Enzypep B.V.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,450,084 | Chemo-enzymatic peptide synthesis via C-terminal ester interconversion Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,598,714 | Side-chain protected oligopeptide fragment condensation using subtilisins in organic solvents Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,138,268 | Peptide Fragment Condensation and Cyclisation Using a Subtilisin Variant with Improved Synthesis Over Hydrolysis Ratio Formerly held In force · High confidence | In force | High confidence | |
| US 10,253,061 | Peptide Fragment Condensation and Cyclisation Using a Subtilisin Variant with Improved Synthesis Over Hydrolysis Ratio Formerly held In force · High confidence | In force | High confidence | |
| US 10,752,931 | Designing an enzymatic peptide fragment condensation strategy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,336,994 | Subtilisin Variants Having a Mutation in the S2 or S2' Pocket Formerly held In force · High confidence | In force | High confidence | |
| US 10,858,414 | Chemo-enzymatic synthesis of semaglutide, liraglutide and GLP-1 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,920,258 | Chemo-enzymatic synthesis of semaglutide, liraglutide and GLP-1 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,883,132 | Chemo-enzymatic synthesis of Semaglutide, Liraglutide and GLP-1 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,883,444 | Peptide Synthesis Using Enzymatic Activation an Coupling Lapsed on the fee record Ended Nov 11, 2022 · High confidence | Lapsed on the fee record | Ended Nov 11, 2022 | High confidence |